Total revenue for the third quarter of 2023 was $1.5M, comprised entirely of product sales, a 60% decrease compared to $3.7M in the prior year period, driven by a $1M reduction in BARDA revenue, a $0.4M sepsis test backorder, a $0.3M reduction in international T2Dx Instrument sales, and a $0.3Mreduction in COVID-19 test sales.Cash and cash equivalents totaled $24.3M as of September 30.The Company raised $21.9M in net proceeds through ATM sales in the third quarter of 2023 and on July 6,converted $10M, or approximately 20%, of its term loan into equity.The Company’s third quarter 2023 financial results are preliminary and are subject to the completion of the review of the Company’s third quarter 2023 financial statements. Complete third quarter 2023 financial results will be announced in November.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TTOO:
- T2 Biosystems Announces Preliminary Third Quarter 2023 Financial Results and Business Updates
- T2 Biosystems Announces FDA 510(k) Submission to Expand the Pathogen Detection on its FDA-Cleared T2Bacteria Panel to Include Detection of Acinetobacter baumannii
- T2 Biosystems options imply 67.5% move in share price post-earnings
- T2 Biosystems Announces Reverse Stock Split Effective Today
- T2 Biosystems announces reverse stock split